Category: EN

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions INCHEON, South Korea, Oct. 9, 2025 […]

RE/MAX HOLDINGS, INC. TO RELEASE THIRD QUARTER 2025 RESULTS ON OCTOBER 30, 2025

DENVER, Oct. 9, 2025 /PRNewswire/ — RE/MAX Holdings, Inc. (NYSE:RMAX), parent company of REMAX, one of the world’s leading franchisors of real estate brokerage services, and Motto Mortgage, the first and only national mortgage brokerage franchise brand in the U.S., will release financial results for the quarter ended September 30, 2025, after market close on Thursday, […]

Amplifi Vascular Announces Successful First-in-Human Study Results, Closes $6.8M Series A, and Receives FDA IDE Approval

Company announces positive first-in-human study results, the close of a $6.9 million Series A financing, and FDA approval of its Investigational Device Exemption.  ST. LOUIS, Oct. 9, 2025 /PRNewswire/ — Amplifi Vascular, developer of the first-of-its-kind Vein Dilation System designed to increase eligibility, improve creation and early maturation of arteriovenous fistulas (AVFs) for hemodialysis, today […]

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 9, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated […]

Grace Adventures Ministries Announces President Retirement

SILVER LAKE, Mich., Oct. 9, 2025 /PRNewswire/ — Grace Adventures Ministries, a leader equipping students and strengthening families since 1946, announces the retirement of its longtime President, Steve Prudhomme, effective March 31, 2026. After nearly three decades of faithful service, Steve will leave behind a rich legacy of impact, discipleship, and transformed lives. Continue Reading Steve […]

UN Global Compact, African Union and Partners Convene 4th African Business and Human Rights Forum to Advance Remedy, Reparations and Responsible Business in Africa

LUSAKA, Zambia, Oct. 9, 2025 /PRNewswire/ — The 4th African Business and Human Rights Forum (ABRH) concluded today in Lusaka, Zambia, bringing together more than 600 participants, including business leaders, governments, civil society, Indigenous Peoples, national human rights institutions and international partners, to advance the implementation of the United Nations Guiding Principles on Business and […]

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK

NEW YORK, Oct. 9, 2025 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”), of the important November 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cytokinetics common stock […]